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In addition to Th1 and Th2 cells, it is now ac-
cepted that naive CD4+ T cells can differentiate 
into Th17 or Th22 cells that secrete IL-17 or 
IL-22, respectively (Annunziato and Romagnani, 
2009; Zhou et al., 2009; Wolk et al., 2010). 
Th17 cells mediate proinflammatory immune 
responses against some species of extracellular 
bacteria and most fungal pathogens (Bettelli et al., 
2006;  Holland  et  al.,  2007;  Minegishi  et  al., 
2007; de Beaucoudrey et al., 2008). Th17 cells 
are  also  broadly  implicated  in  the  patho-
genesis of many common autoimmune dis-
orders, including multiple sclerosis, rheumatoid 
arthritis  (RA),  psoriasis,  and  inflammatory 
bowel  disease  (Lock  et  al.,  2002;  Cua  et  al., 
2003; Fujino et al., 2003; Langrish et al., 2005; 
Wilson et al., 2007). Th22 cells are involved in 
skin immunity and remodeling but are also im-
plicated in cutaneous inflammatory conditions 
such  as  psoriasis  (Eyerich  et  al.,  2009; Wolk   
et al., 2010). Ex vivo analyses of human periph-
eral  blood T  cells  indicate  that  nearly  all   
IL-17–secreting cells, and the majority of IL-22–
  producing T  cells,  express  the  chemokine   
receptor  CCR6  and  the  transcription  factor 
RORC (Annunziato et al., 2007; Singh et al., 
2008; Duhen et al., 2009; Romagnani et al., 
2009; El Hed et al., 2010). Accordingly, ectopic 
expression of RORC in naive T cells or CCR6   
memory  cells  is  sufficient  to  induce  IL-17   
secretion  (Manel  et  al.,  2008).  Currently,  all   
effector T cell subsets, including Th17 and Th22 
cells, are defined solely based on cytokine ex-
pression  after  ex  vivo  stimulation  (Duhen   
et al., 2009). However, it is not clear whether 
this definition accurately reflects the full rep-
ertoire of memory T (TM) cells that have the 
capacity to produce IL-17/IL-22 at sites of 
inflammation.  Moreover,  the  cytokines  and 
downstream  signaling  pathways  that  control   
IL-17/IL-22  secretion  in  lineage-committed 
TM cells remain uncharacterized.
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Human memory T cells (TM cells) that produce IL-17 or IL-22 are currently defined as Th17 
or Th22 cells, respectively. These T cell lineages are almost exclusively CCR6+ and are impor-
tant mediators of chronic inflammation and autoimmunity. However, little is known about 
the mechanisms controlling IL-17/IL-22 expression in memory Th17/Th22 subsets. We show 
that common  chain (c)–using cytokines, namely IL-2, IL-7, and IL-15, potently induce 
Th17-signature cytokine expression (Il17a, Il17f, Il22, and Il26) in CCR6+, but not CCR6, 
TM cells, even in CCR6+ cells lacking IL-17 expression ex vivo. Inhibition of phospho-
inositide 3-kinase (PI-3K) or Akt signaling selectively prevents Th17 cytokine induction by  
c-cytokines, as does ectopic expression of the transcription factors FOXO1 or KLF2, which are 
repressed by PI-3K signaling. These results indicate that Th17 cytokines are tuned by PI-3K 
signaling in CCR6+ TM cells, which may contribute to chronic or autoimmune inflammation. 
Furthermore, these findings suggest that ex vivo analysis of IL-17 expression may greatly 
underestimate the frequency and pathogenic potential of the human Th17 compartment.
© 2011 Wan et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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define  human T  cells  that  have  the  capacity  to  express   
IL-17, even if they lack IL-17 expression ex vivo. To address 
this possibility, we FACS sorted primary human CD4+-
CD45RO+CD25 TM cells stimulated either with beads con-
jugated  to  anti-CD3  and  anti-CD28  (aCD3/aCD28) 
antibodies or with PMA and ionomycin into CCR6IL-17, 
CCR6+IL-17+, or CCR6+IL-17 subsets using a cytokine 
capture assay (Fig. 1 A and Fig. S1 A). Analyses of gene expres-
sion  directly  after  sorting  confirmed  that  Il-17a  transcript   
levels were substantially higher in CCR6+IL-17+ cells com-
pared with either CCR6 or CCR6+IL-17 cells, irrespec-
tive of the activating stimuli (i.e., aCD3/aCD28 or PMA and 
ionomycin). However, both CCR6+ T cell subsets displayed 
elevated  RORC  expression  levels  that  ranged  between   
80- and 400-fold higher than those observed in CCR6 TM 
cells (Fig. 1 B and Fig. S1 B; Singh et al., 2008). Given that 
RORC was highly expressed in CCR6+ TM cells independent 
of ex vivo IL-17 production, we next cultured these T cell 
subsets in IL-2–supplemented medium for 6 d to ask whether 
CCR6+IL-17 cells could up-regulate IL-17 expression. As 
expected, a large majority of cells initially sorted as CCR6+ 
IL-17+ maintained high-level IL-17 expression upon restim-
ulation, whereas CCR6IL-17 cells remained largely IL-17 
negative (Fig. 1 C and Fig. S1 C). Remarkably, 20–40% of the 
CCR6+ cells initially sorted as IL-17 expressed IL-17 after 
culture with IL-2 (Fig. 1 C and Fig. S1 C). The appearance of 
IL-17–producing T  cells  within  ex  vivo–isolated  CCR6+ 
IL-17 cultures was not a result of selective outgrowth of re-
sidual  IL-17+  cells,  as  FACS-sorted  CCR6+IL-17  and 
CCR6+IL17+ cells proliferated equally well in response to IL-2 
stimulation, as seen by fluorescent dye dilution and mixed   
co-culture experiments (Fig. S1, D–G).
A more comprehensive analysis of cytokine gene expres-
sion by human CCR6+IL-17 and CCR6+IL-17+ cells re-
vealed that these two cell types were nearly indistinguishable 
after culture with IL-2. Specifically, several proinflamma-
tory cytokines canonically associated with the Th17 lineage   
(IL-17a, IL-17f, IL-22, IL-26, Ccl20, and IL-21) were com-
parably expressed in both CCR6+IL-17 and CCR6+IL-17+ 
cells, although both CCR6+ cell types expressed substantially 
higher levels of these cytokines compared with CCR6 TM 
cells (Fig. 1 D). Importantly, differential expression of Th17-
signature cytokines by both CCR6+ populations compared 
with CCR6 T cells was specific, as all three populations ex-
pressed roughly equivalent levels of other cytokines not re-
lated to the Th17 lineage, namely Tnf, Il4, and Ifng (Fig. 1 D).
Given that IL-2 is the prototype of the IL-2 family of cyto-
kines, all of which signal through cytokine receptors com-
prised in part by the c subunit, we next asked whether other 
c-cytokines could also induce de novo IL-17 production by 
CCR6+IL-17 TM cells. Both IL-7 and IL-15 induced similar 
levels of IL-17 expression in CCR6+IL-17 T cells, whereas 
IL-23, which is known to enhance Th17 cell differentiation 
(Ivanov et al., 2007), did not influence IL-17 expression in 
the absence of IL-2 (Fig. 1 E). In contrast, and as observed for 
IL-2, neither IL-7 nor IL-15 induced IL-17 expression in 
The IL-2 family of cytokines, which signal through mul-
timeric receptors containing the shared common  chain (c) 
subunit, includes IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. 
These  cytokines,  particularly  IL-2,  IL-7,  and  IL-15,  play   
pivotal roles in promoting T cell development, homeostasis, 
and differentiation. In addition to activating Jak–Stat path-
ways,  c  signaling  induces  the  generation  of  lipid  second 
messengers through activation of phosphoinositide 3-kinase 
(PI-3K; Rochman et al., 2009). One of these second messen-
gers, PI(3,4,5)P3 (phosphatidylinositol-(3,4,5)-trisphosphate), 
binds to the PH (pleckstrin homology) domain of proteins 
and controls the activity and function of several signaling 
molecules, including the serine/threonine protein kinase Akt 
(Fruman, 2004). In turn, Akt directly phosphorylates the tran-
scription factor FOXO1 (Forkhead box protein O1), thereby 
preventing its nuclear translocation and transcriptional activ-
ity (Brunet et al., 1999). Inhibition of FOXO1 by PI-3K has 
been shown to be essential for c-cytokine signaling–mediated 
cell survival, proliferation, and glucose utilization in leukemia 
cells (Barata et al., 2004). In contrast, activation of FOXO1, by 
way of reduced PI-3K signaling, can lead to the expression of 
another transcription factor called KLF2 (kruppel-like fac-
tor 2; Sinclair et al., 2008; Kerdiles et al., 2009), which has 
been implicated in the modulation of IFN- and IL-4 pro-
duction in human and mouse T cells (Weinreich et al., 2009, 
2010; Bu et al., 2010). However, whether FOXO1 or KLF2 
act downstream of PI-3K to regulate effector cytokine pro-
duction in human TM cells is not yet known.
In searching for stimuli that regulate the production of 
IL-17 and IL-22 in human TM cells, we found that c-cytokines, 
notably IL-2, IL-7, or IL-15, are sufficient to induce de novo 
expression of IL-17, IL-22, and other Th17-signature cyto-
kines in CCR6+, but not CCR6, TM cells. Treatment of   
cytokine-stimulated CCR6+ TM cells with small molecule   
inhibitors  of  PI-3K  or Akt  repressed  c-cytokine–driven   
IL-17/IL-22 expression, as did ectopic expression of FOXO1 
or  KLF2.  These  findings  suggest  that  PI-3K  signaling   
may amplify Th17- or Th22-associated tissue inflamma-
tion  by  promoting  proinflammatory  cytokine  expression  in   
lineage-committed  human  Th17/Th22  cells.  Our  results   
also demonstrate that the frequency of human TM cells har-
boring the capacity to secrete IL-17/IL-22 in vivo may be 
substantially higher than what is predicted based on ex vivo 
cytokine analysis.
RESULTS
De novo induction of IL-17 in CCR6+ IL-17 T cells is driven 
by c-cytokines
Nearly all T cells defined as Th17, by virtue of IL-17 expres-
sion, also express CCR6, although only a fraction of CCR6+ 
T cells (5–10%) actively express IL-17 upon ex vivo stimu-
lation. Given that both CCR6 and IL-17 are up-regulated by 
ectopic expression of RORC in human T cells (Manel et al., 
2008) and that CCR6 is a direct target gene of the key Th17 
transcription factor Stat3 (Durant et al., 2010), we hypothe-
sized that expression of this chemokine receptor may broadly JEM Vol. 208, No. 9 
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IL-17 induction in response to c-cytokine stimulation  
is conserved in heterogeneous CCR6+ TM cell subsets
Human CCR6+ Th17 cells have been reported to be en-
riched within CXCR3 or CD161+ subsets as cells of these 
subphenotypes produce more IL-17 upon ex vivo stimulation 
compared with either CCR6+CXCR3+ or CCR6+CD161 
cells (Acosta-Rodriguez et al., 2007; Cosmi et al., 2008). We 
confirmed that a significant proportion of human CCR6+ TM 
cells coexpressed either CD161 or CXCR3 and that CD161 
expression was enriched within CCR6+ cells, whereas ex-
pression of CXCR3 was enriched within the CCR6 com-
partment (Fig. 2 A). As expected, CCR6+CD161+ TM cells 
were  enriched  for  IL-17–producing  cells  upon  ex  vivo   
stimulation compared with CCR6+CD161 cells, whereas 
CCR6+CXCR3+ cells produced less IL-17 but more IFN- 
than CCR6+CXCR3 cells (Fig. 2 A). To address the possi-
bility that IL-17 up-regulation by CCR6+IL-17 cells is re-
stricted to predefined CCR6+ subpopulations, we fractionated 
CCR6+IL-17 cells based on either CD161 or CXCR3 expres-
sion and expanded these subsets in the presence of IL-2 (Fig. 2 A).   
CCR6 TM  cells.  In  addition,  CCR6+,  but  not  CCR6,   
IL-17 TM cells isolated from peripheral lymphoid organs of 
wild-type C57B/6 mice were capable of producing IL-17   
after 6 d in culture with IL-2 (Fig. S2).
These findings suggest that ex vivo analyses of IL-17 ex-
pression underestimate the frequency of TM cells that can 
express IL-17 in inflammatory settings. Because several studies 
have investigated changes in Th17 frequencies within auto-
immune  patient  cohorts,  we  asked  whether  CCR6+IL-17  
TM cells isolated from the peripheral blood of patients with 
RA could be similarly induced to express IL-17 by IL-2 stimu-
lation. Indeed, we observed that CCR6+, but not CCR6,   
IL-17 TM cells from RA patients up-regulated IL-17 after 
culture with IL-2 to similar levels as those observed in healthy 
adult donors (Fig. 1 F). Collectively, these data demonstrate 
that CCR6+ TM cells are uniquely poised to express IL-17 in 
response to IL-2 stimulation irrespective of their IL-17 phe-
notype ex vivo. These results also indicate that this inflamma-
tory feature of CCR6+ TM cells is conserved between humans 
and mice.
Figure 1.  De novo expression of IL-17 in CCR6+IL-17 human TM cells is induced by c-cytokines. (A) Total CD4+ TM cells (CD45RO+CD25) were stim-
ulated for 18–24 h with aCD3/aCD28 beads and then were FACS sorted into CCR6IL-17, CCR6+IL-17, or CCR6+IL-17+ populations by cytokine capture assay. 
(B) Cells sorted as in A after aCD3/aCD28 stimulation were analyzed by quantitative (q) PCR for expression of Il-17a and Rorc gene expression. Data are pre-
sented as the mean fold change from duplicates from one representative donor and are derived from Ct values (qPCR) ± SD from duplicate samples. The data 
were obtained from a single donor that is representative of two to three independent experiments using T cells from different donors. (C) Live CCR6IL-17, 
CCR6+IL-17, or CCR6+IL-17+ T cells were maintained in IL-2–containing medium for 6–7 d and were restimulated with PMA and ionomycin. Cytokine produc-
tion was determined by intracellular staining. (D) Cytokine gene expression was determined using qNPA (see Materials and methods) in CCR6IL17, CCR6+ 
IL-17, or CCR6+IL-17+ populations expanded for 7 d in IL-2–supplemented medium and restimulated with PMA and ionomycin. Cytokine mRNA expression was 
normalized to a housekeeping gene (Rpl19) and normalized values are presented as a fold change on a scatter plot (where x axis = CCR6+IL-17/CCR6IL-17 
and y axis = CCR6+IL-17+/CCR6IL-17). Data from A–D is representative of three independent donors. (E) FACS-sorted CCR6IL-17 cells (white bars), or 
CCR6+IL-17 cells (black bars) sorted as in A, were cultured in different cytokine conditions as indicated for 6 d. IL-17 expression was determined by FACS analy-
sis after restimulation with PMA and ionomycin. Data are presented as the mean percentage of cells ± SD from three different donors. (F) CCR6+IL-17 TM cells 
are specifically poised to express IL-17 in human RA patients. Total CD4+ TM cells isolated from the peripheral blood of RA patients were either stimulated directly 
ex vivo (day 0) with PMA and ionomycin or were stimulated and FACS sorted as in A into CCR6IL-17 or CCR6+IL-17 cells. These cells were cultured in IL-2–
supplemented medium for 7 d before restimulation with PMA and ionomycin (day 7). The frequencies of IL-17–producing cells were determined via intracellular 
staining and FACS analysis. Data represent the mean (horizontal bars) percentage of IL-17-producing cells from four individual RA patients.1878 Regulation of Th17 cytokine production by human T cells | Wan et al.
PI-3K/Akt signaling mediates Th17 cytokine induction  
by c-cytokines
We have previously shown that c-cytokines, such as IL-7, 
can promote T cell survival in the absence of TCR signaling 
and do so without inducing significant cell division (Unutmaz 
et al., 1994, 1999). Given that IL-7 and IL-15 could sub-
stitute  for  IL-2  in  inducing Th17  cytokine  expression  in 
TCR-activated CCR6+ TM cells, we next asked whether   
c-cytokine signaling was sufficient to promote IL-17/IL-22 
expression in resting human CCR6+ TM cells not stimulated 
through the TCR (Fig. 3 A). Indeed, stimulation of resting 
CCR6+CD45RO+CD25 TM  cells  with  IL-7  for  10  d 
After expansion and restimulation, we found that all CCR6+ 
IL-17 subsets were capable of high-level IL-17 production in 
contrast to CCR6 TM cells (Fig. 2, B and C). Consistent with 
the ex vivo analyses of these subsets, however, the frequency 
of IL-17+ cells was somewhat higher (approximately twofold) 
in the CD161+ or CXCR3 subsets compared with CD161 
or  CXCR3+  counterparts,  respectively  (Fig.  2,  B  and  C). 
Moreover, CCR6+CXCR3+IL-17 cells maintained their pro-
pensity to express IFN- as compared with CCR6+CXCR3 
memory cells (Fig. 2 C). These data demonstrate that hetero-
geneous subpopulations of CCR6+ T cells share a capacity to 
express IL-17 in response to c-cytokine stimulation.
Figure 2.  IL-17 induction in response to c-cytokine stimulation is a conserved feature shared by heterogeneous CCR6+ TM cell subsets.  
(A) Ex vivo (day 0) isolated CD4+ TM cells were costained with CCR6, CD161, and CXCR3. The frequency of CCR6+ cells positive or negative for either 
CD161 (left) or CXCR3 (right) are shown. Ex vivo cytokine production was determined after PMA and ionomycin stimulation within each gated CCR6+  
TM cell subset as indicated. FACS plots show the intracellular expression of IL-17, IL-22, and IFN-. (B) FACS-sorted CCR6IL-17, CCR6+CD161+/IL-17 
(left), or CCR6+CXCR3+/IL-17 (right) cells were cultured in IL-2–supplemented medium for 7 d and restimulated with PMA and ionomycin. Cytokine 
production was determined by intracellular staining for IL-17, IL-22, and IFN-. Each set of data is representative of three donors.JEM Vol. 208, No. 9 
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Figure 3.  PI-3K/Akt inhibitors suppress IL-17 and IL-22 production from IL-7–stimulated CCR6+ TM cells. (A) Resting CD4+CD45RO+CD25CCR6+/  
T cells were cultured in IL-7–containing medium for 7 d followed by culture with or without PI-3K signaling inhibitors for an extra 2 d. Cells were then 
stimulated with PMA and ionomycin and subjected to intracellular staining and FACS analysis as described in Materials and methods. (B) Blockade of PI-3K 
signaling suppresses IL-17 and IL-22 production induced by IL-7 from CCR6+ TM cells. Intracellular cytokine staining was performed on CCR6+ and  
CCR6 TM cells ex vivo (day 0) and after different culturing conditions (day 10) as described in A. CCR6+/ TM cells were cultured with IL-7 alone  
or plus 5 µg/ml LY294002 or 5 µg/ml AKTi-1/2. (C) Frequency of IL-17–producing T cells is increased by c-cytokine stimulation across different donors. 
CCR6+ TM cells isolated from seven healthy donors (D) were stimulated either ex vivo or at day 10 after culture with IL-7. (D and E) PI-3K and Akt inhibitors 
inhibit IL-17, IL-22, and IL-4 expression in IL-7–activated CCR6+ TM cells in a dose-dependent manner. Cells cultured in IL-7 with or without LY294002 or 
AKTi-1/2 at different concentrations (µg/ml) were collected and analyzed. The frequency of single (D) or double (E) cytokine-producing cells without inhibi-
tors treatment (control, 0) was normalized to 100%. Cytokine percentage of control was calculated accordingly. Data are presented as the mean percentage 
cytokine ± SD from at least three different donors. (F) Cytokine gene expression in CCR6+/CCR6 TM cells. Different cytokine gene expression was analyzed 
by qNPA from either ex vivo freshly isolated CCR6+ (filled rectangle) or CCR6 (empty rectangle) cells at day 0 (d0) and day 10 (d10) after culturing in IL-7–
containing medium in the absence or presence of 5 µg/ml PI-3K/Akt inhibitors. Data from CCR6+ TM cells are presented as mean mRNA abundance (AU) ± SD 
from three different donors. The statistical analyses, either ex vivo or at day 10 with PI-3K inhibitor treatments, are relative to day 10 IL-7 only (filled blue 
rectangle). Data from CCR6 is representative out of three donors. *, P < 0.05; **, P < 0.005; ***, P < 0.001. NS, no significance.1880 Regulation of Th17 cytokine production by human T cells | Wan et al.
consistently  enhanced  the  expression  of  both  IL-17  and   
IL-22 more than threefold compared with the same cells isolated 
ex vivo (day 0; Fig. 3, B and C). Importantly, IL-7–mediated 
induction of IL-17 and IL-22 expression was restricted to 
CCR6+ cells, as CCR6 TM cells stimulated with IL-7 failed 
to express IL-17 or IL-22 (Fig. 3 B). Moreover, culture of 
resting CCR6+ or CCR6 TM cells with IL-7 had almost no 
impact on IFN- production (Fig. 3, B and C). Stimulation of 
resting CCR6+ TM cells with IL-15 led to similar increases in 
IL-17/IL-22 expression (unpublished data), whereas another 
c-cytokine, IL-4, did not promote Th17 cytokine produc-
tion in resting CCR6+ TM cells or confer TM cell survival   
(Fig. S3 B and not depicted). Interestingly, IL-23 did not sig-
nificantly synergize with IL-7 to further induce IL-17 or   
IL-22 expression (Fig. S3 B).
Human CCR6+ T cells can express IL-17 alone or in 
combination with other proinflammatory cytokines such as 
IL-22 or IFN-. Cells coexpressing IFN- and IL-17 have 
been shown to share functional characteristics with those ex-
pressing  IL-17  alone  (Boniface  et  al.,  2010),  whereas  the 
function of IL-17+IL-22+ cells is unclear. IL-7 stimulation 
had even more profound effects on the proportion of cells 
that coexpressed either IL-22 or IFN- with IL-17; these 
double cytokine-producing cells increased more than fivefold 
in response to IL-7 signaling (Fig. 3 B). Together, these results 
demonstrate that c-cytokines, particularly IL-2, IL-7, and 
IL-15 potently enhance IL-17/IL-22 secretion by CCR6+ 
TM cell subsets.
Signaling through c-containing cytokine 
receptors regulates T cell survival and homeosta-
sis through activation of the PI-3K–Akt pathway 
(Rochman et al., 2009). To determine if this pathway also 
controls expression of IL-17 and IL-22, we treated CCR6+ 
TM cells that had been cultured for 1 wk in IL-7 with or 
without the PI-3K inhibitor LY294002 or the Akt inhibitor 
AKTi-1/2 for additional 48 h (Fig. 3 A). We confirmed that 
treatment of Jurkat cells with 1–10 µg/ml of either inhibitor 
down-regulated cytokine-dependent phosphorylation of Akt 
without adversely affecting cell viability (Fig. S3 A). Control- 
or compound-treated T cells were then restimulated to ana-
lyze their impact on cytokine production. Treatment with 
either LY294002 or AKTi-1/2 repressed c-mediated IL-17/
IL-22 induction in a dose-dependent manner, whereas ex-
pression of IL-4 or IFN- was either less reduced or not 
affected, respectively (Fig. 3, B, D, and E). Inhibitory effects of 
the PI-3K and Akt inhibitors were even more profound when 
considering the proportion of T cells coexpressing IL-22 or 
IFN- together with IL-17 (Fig. 3 E). Furthermore, treat-
ment with PI-3K or Akt inhibitors also repressed IL-17 and 
IL-22 expression in TCR-activated CCR6+ TM cells cultured 
in IL-2 (Fig. S3, C–E). These effects were reversible because 
IL-17/IL-22 levels were restored upon removal of PI-3K or 
Akt  inhibitors  from  culture  medium  (unpublished  data). 
Moreover, IL-17/IL-22 repression by PI-3K or Akt inhibi-
tion was not associated with changes in Rorc or Foxp3 expres-
sion levels (Fig. S3 F).
We next evaluated the impact of PI-3K or Akt inhibition 
on the expression of a broader panel of both Th17-related and 
unrelated cytokines to determine how selectively this pathway 
Figure 4.  IL-17/IL-22 production from CCR6+  
TM cells is suppressed by ectopic FOXO1 expression.  
(A) T cells activated through their TCR were transduced with 
FOXO1-GFP and cultured in IL-2 for 14 d then stimulated 
with PMA and ionomycin, stained for intracellular cyto-
kines, and subjected to FACS analysis. (B) The frequency  
of single or double cytokine-producing cells from FOXO1  
or EV-transduced cells is shown. The horizontal bars are 
presented as mean frequency of cytokine producing  
cells from four independent individuals. *, P < 0.05.  
NS, no significance.
Figure 5.  Klf2 expression is regulated by 
c-cytokine–induced PI-3K signaling 
pathway. (A) Klf2 message is abundant in 
resting CD4+ T cells and down-regulated upon 
activation through the TCR. Total cellular RNA 
was extracted from cell pellets of resting 
aCD3/aCD28 bead–activated CD4+ TM cells. 
The RNA was subjected to RT-qPCR for Klf2 
and b-actin mRNA quantification. (B) Blockade  
of PI-3K signaling by LY294002 treatment up-regulates Klf2 transcripts in a dose-dependent manner in CCR6+ TM cells cultured in IL-7. CCR6+ TM cells 
were cultured in IL-7–containing medium as in Fig. 3 A. Total RNA from either ex vivo freshly isolated (day 0) or cultured in IL-7 (day 10) with or without 
LY294002 at the indicated concentrations was collected and subjected to RT-qPCR to detect Klf2 levels. (C) Ectopic transduction of KLF2 in TCR-activated 
IL-2–cultured TM cells maintains Klf2 message levels comparable to resting cells. Data shown is from one representative of three different donors.JEM Vol. 208, No. 9 
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regulates inflammatory cytokine expression. In addition to 
IL-17A, IL-17F, and IL-22, Th17 cells have been shown to 
preferentially  express  IL-21  (Nurieva  et  al.,  2007),  IL-26   
(in human cells), CCL20 (Wilson et al., 2007), and, in some 
instances, IL-10 (Zhu and Paul, 2010). Although intracellular 
IL-10 production was not detectable in either CCR6+ or 
CCR6 TM cells upon stimulation ex vivo or after culture 
with IL-7, we found that, unlike IL-17 and IL-22, ex vivo 
production of IL-21 was equivalent in both human CCR6 
and CCR6+ TM cell subsets (Fig. S4, A and B). Similarly, and 
in contrast to IL-17 and IL-22, expression of IL-21 was not 
increased in either CCR6+ or CCR6 TM cells upon stimu-
lation with IL-7, and in fact was slightly reduced (Fig. 3 F; and 
Fig. S4, A and B). IL-21 expression was, however, sensitive to 
treatment with PI-3K or Akt inhibitors (Fig. S4, A and B). 
Ccl20 was preferentially expressed ex vivo by CCR6+ TM 
cells (Fig. 1 D) and was neither significantly induced by IL-7 
stimulation nor repressed by PI-3K pathway inhibition (Fig. 3 F  
and Fig. S4 C). The expression of other non–Th17-related 
cytokines, such as Il2, Ifng, Tnf, and Tgfb1 were not influenced 
by IL-7 stimulation or by treatment with PI-3K or Akt in-
hibitors (Fig. 3 F and Fig. S4 C). Thus, PI-3K signaling down-
stream of c-cytokine receptors promotes the expression of 
Th17-signature  cytokines  (Il-17a,  Il-17f,  and  Il-22)  within 
CCR6+ TM cells and does so with a high degree of specificity 
over other unrelated cytokines.
FOXO1 and KLF2 repress IL-17/IL-22 expression
PI-3K  activation  downstream  of  c-cytokine  stimulation 
negatively regulates FOXO1 nuclear localization and tran-
scriptional activity (Birkenkamp and Coffer, 2003). Because 
we found cytokine-driven IL-17 and IL-22 expression by 
CCR6+ TM cells to be sensitive to PI-3K or Akt inhibition, 
we next asked whether ectopic expression of FOXO1 could 
also  repress  c-mediated  IL-17/IL-22  expression.  Human 
CCR6+ TM cells were activated and transduced with control 
(empty vector [EV]) or FOXO1-expressing lentiviruses and 
then expanded in the presence of IL-2, FOXO1 overexpres-
sion was confirmed by intracellular staining (Fig. S5 A), and 
these cells were then restimulated to evaluate effects on cyto-
kine production. Analogous to treatment of cells with PI-3K 
and Akt  inhibitors,  FOXO1  overexpression  reduced  both   
IL-17 and IL-22 secretion (Fig. 4, A and B).
Another transcription factor, KLF2, is also reported to be 
negatively regulated by PI-3K signaling (Sinclair et al., 2008). 
Unlike FOXO1, however, KLF2 is repressed by PI-3K signal-
ing primarily at the level of gene expression (Weinreich et al., 
2009). To  investigate  whether  KLF2  may  regulate  IL-17/ 
IL-22 secretion by CCR6+ TM cells, we first analyzed the   
kinetics of Klf2 mRNA expression in TM cells. Consistent with 
previous studies (Kuo et al., 1997a; Grayson et al., 2001;   
Wu and Lingrel, 2005), we found that Klf2 expression was 
rapidly  down-regulated  after TCR  activation  (>100-fold;   
Fig. 5 A). Klf2 mRNA expression rebounded somewhat after 
extended culture of TCR-activated T cells in IL-2, although 
even under these conditions Klf2 mRNA levels remained 
Figure 6.  KLF2 suppresses IL-17 and IL-22 production from CCR6+ 
TM cells in the presence of ectopic RORC expression. (A and B) KLF2- 
or shKLF2-transduced CCR6+ TM cells cultured for 2 wk in IL-2 medium 
were treated with PMA and ionomycin and then subjected to intracellular 
IL-17, IL-22, IFN-, and IL-4 staining. shCont., control shRNA; shKLF2, 
KLF2 shRNA. The frequency of single or double cytokine-producing cells 
from either EV- or control shRNA–transduced cells was normalized to 
100%. (C) RORC overexpression and silencing of KLF2 are synergistic on 
induction of IL-17. CCR6 TM cells co-transduced with shKLF2- and 
RORC-expressing lentiviruses or their corresponding controls were re-
stimulated with PMA and ionomycin for 5 h. Cells were then stained with 
antibodies against IL-17, IL-22, IFN-, and IL-4 and shown as dot plots  
in C from a representative donor or, graphically, from multiple donors in D. 
Data are presented as mean percentage of cytokine ± SD from at least 
three individual donors and independent experiments. *, P < 0.05;  
**, P < 0.005. NS, no significance.1882 Regulation of Th17 cytokine production by human T cells | Wan et al.
These results also suggest that current methods of calcu-
lating Th17 cell frequencies based solely on ex vivo IL-17 
production may not represent the true size or inflammatory 
potential of the human Th17 memory cell compartment. This 
becomes particularly important for how Th17 cells are evalu-
ated and quantified in clinical disease settings. Indeed, we 
have found that a substantial portion of CCR6+, but not 
CCR6, IL-17 TM cells isolated ex vivo from the peripheral 
blood of RA patients convert into IL-17 producers upon cul-
ture with c-cytokines (Fig. 1 F).
The ability of CCR6+ TM cells to express IL-17 may be a 
result of the fact that, in contrast to CCR6 TM cells, CCR6+ 
cells express high levels of RORC ex vivo, independent of   
IL-17. This is indeed likely given that ectopic expression of 
RORC can induce IL-17 expression in CCR6 TM cells 
(Fig. 6; Manel et al., 2008). These findings further suggest that 
RORC is necessary, but not sufficient, for IL-17 production 
by human TM cells. We propose that RORC synergizes with 
c-mediated PI-3K and Akt signaling to trans-activate IL-17 
expression. Two additional results support a model in which 
c-cytokine signaling acts together with RORC to control 
IL-17 production by itself, as opposed to regulating Th17   
lineage commitment. First, IL-7 stimulation, treatment with 
PI-3K or Akt inhibitors, and overexpression of FOXO1 or 
KLF2 did not affect RORC mRNA expression levels (Fig. S3 F 
and not depicted). Second, inhibition of IL-17 and IL-22 ex-
pression by treatment with LY294002 was completely revers-
ible (unpublished data).
IL-23 is another cytokine thought to be important for the 
stability and proinflammatory functions of Th17 cells, partic-
ularly in the mouse (Zheng et al., 2007; Zhou et al., 2007). 
However, we found that IL-23 was not able to compensate 
for c-cytokines in the induction of IL-17/IL-22 expression 
from CCR6+ human TM cells, even though these cells ex-
pressed Il23R mRNA (unpublished data). Conceivably, IL-23 
could enhance IL-17–secreting cells but this effect may be at-
tributed to preferential expansion of CCR6+IL-23R+ TM cells 
that are more likely to express IL-17 upon TCR triggering.   
It is also reasonable to speculate that a more dominant role of 
IL-23 in driving IL-17–associated pathology is through its re-
ported effects on IL-17 expression within TCR-/ lym-
phocytes or other innate immune cells (Moens et al., 2011).
PI-3K is activated in T cells in response to TCR engage-
ment  or  c-cytokine  stimulation  (Rochman  et  al.,  2009; 
Smith-Garvin et al., 2009), which in turn results in the phos-
phorylation and activation of Akt (Coffer et al., 1998). On 
one hand, PI-3K/Akt signaling positively regulates cell me-
tabolism through activation of mTORC1 (Gibbons et al., 
2009). On the other hand, activated Akt also inhibits the tran-
scriptional activity or expression of FOXO1 or KLF2, respec-
tively (Fabre et al., 2008; Sinclair et al., 2008). We found that 
the induction of IL-17 and IL-22 expression by c-cytokines 
was reversed by short-term (48 h) treatment with PI-3K or 
Akt inhibitors. Furthermore, overexpression of either FOXO1 
or KLF2 recapitulated the effects of the PI-3K or Akt inhibitors 
on IL-17 and IL-22 induction. Conversely, shRNA-mediated 
10–20-fold lower than those seen in resting T cells (Fig. 5 A). 
Klf2 expression was also decreased in resting CCR6+ TM cells 
upon stimulation with IL-7 alone (Fig. 5 B). These data indi-
cate that c-dependent induction of IL-17/IL-22 parallels 
Klf2 down-regulation. Importantly, treatment of TM cells 
with PI-3K/Akt inhibitors reversed cytokine-mediated Klf2 
down-regulation (Fig. 5 B and Fig. S5 B).
To directly address the putative function of PI-3K–mediated 
Klf2 down-regulation on IL-17 and IL-22 expression, we re-
stored KLF2 expression in cytokine-stimulated TM cells using 
lentiviral transduction (Fig. S5 C). Human TM cells transduced 
with  KLF2-expressing  lentiviruses  displayed  Klf2  mRNA 
levels comparable to either resting T cells (Fig. 5 C) or cyto-
kine-stimulated T cells treated with LY294002 (Fig. 5 B). 
Upon restimulation, human CCR6+ TM cells ectopically ex-
pressing KLF2 produced less IL-17 or IL-22 compared with 
cells transduced with control lentiviruses (Fig. 6, A and B), 
whereas neither IFN- nor IL-4 was affected (Fig. 6 A). In 
contrast to KLF2 overexpression, shRNA-mediated silencing 
of endogenous KLF2 (Fig. S5 D) enhanced IL-17/IL-22 se-
cretion by human CCR6+ TM cells (Fig. 6, A and B). Inter-
estingly, T  cells  expressing  KLF2  shRNA  also  displayed 
enhanced IL-4 expression, particularly within the CCR6+ sub-
set (Fig. 6 A), suggesting that KLF2 may regulate expression of 
a broader set of cytokines in TM cell subsets.
CCR6 TM cells also express KLF2, and shRNA-mediated 
knockdown of KLF2 in these cells also enhanced residual   
IL-17 or IL-22 expression (Fig. 6, C and D). Because high-level 
IL-17 expression by CCR6 TM cells can only be achieved by 
forced expression of RORC (Fig. 6, C and D; Manel et al., 
2008),  we  next  asked  whether  KLF2  regulates  RORC- 
mediated  IL-17  expression  in  CCR6 TM  cells.  Indeed, 
knockdown  of  KLF2  further  enhanced  RORC-induced   
IL-17 production in CCR6 TM cells (Fig. 6, C and D). These 
findings  suggest  that  endogenous  KLF2  restrains  RORC- 
mediated induction of IL-17.
DISCUSSION
In this paper, we show that Th17-signature cytokines, par-
ticularly IL-17 and IL-22, are dynamically regulated within 
human CCR6+ TM cells by c-cytokine signals. IL-17 and 
IL-22  expression  by  CCR6+ TM  cells  is  controlled  by   
PI-3K/Akt-dependent signaling that involves the repression 
of both FOXO1 and KLF2. We also report that CCR6 ex-
pression on nonregulatory (i.e., CD25) TM cells broadly 
defines lineage-committed Th17 cells; phenotypically diverse 
subpopulations of CCR6+ (e.g., CD161+/, CXCR3+/)   
TM cells all share a capacity to express Th17 cytokines in re-
sponse to c-cytokine stimulation, irrespective of whether 
or not they express IL-17 ex vivo. Importantly, we show 
that the specific conversion of ex vivo–isolated CCR6+, 
but  not  CCR6IL-17, TM  cells  is  conserved  in  mice   
(Fig. S2). Collectively, these results suggest that IL-17 and 
IL-22 production by CCR6+ TM cells may be influenced 
in a bystander fashion by c-cytokines present at sites of 
inflammation or infection.JEM Vol. 208, No. 9 
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In conclusion, our data indicate that human CCR6+ TM 
cells represent a broad proinflammatory effector lineage 
that expresses IL-17 and IL-22 in a dynamic manner relying 
on  synergy  between  c-cytokine  signaling  and  RORC.  
Local immune responses and subsequent accumulation of   
c-cytokines may thus contribute to  Th17/Th22-driven inflam-
mation, which may be sensitive to PI-3K- or Akt-targeted 
therapies. Moreover, our findings strongly suggest that ex vivo 
analyses of IL-17 and IL-22 secretion may vastly underesti-
mate the true frequency and proinflammatory potential of 
Th17/Th22 cells in vivo. These results shed new light on the 
regulation of proinflammatory cytokine production by human 
TM cells and also call for a broader phenotypic definition of 
Th17/Th22 subsets within both healthy human donors and 
autoimmune patient populations.
MATERIALS AND METHODS
Human T cell purification and activation. PBMCs from healthy indi-
viduals  (New York  Blood  Center,  New York,  NY)  were  prepared  using   
Ficoll-plaque plus (GE Healthcare). Whole blood samples from RA patients 
were purchased from Bioreclamation and were processed similar to healthy 
donor blood. All healthy donor and patient samples were consented before 
purchase,  were  none-identifiable,  and  were  approved  by  the  institutional   
human subjects board. CD4+ T cells were isolated using Dynal CD4 Positive 
Isolation kit (Invitrogen) directly from purified PBMCs and were >99% 
pure.  CD4+ T  cells  were  sorted  by  a  FACSAria  cell  sorter  (BD)  into 
CD45RO+CD25 TM cells. TM cells were activated either by anti-CD3– and 
anti-CD28 (aCD3/aCD28)–coated beads (1:4 bead/cell ratio; Invitrogen) 
for 18–24 h or by 20 ng/ml PMA and 500 ng/ml ionomycin for 4 h and 
further FACS sorted based on CCR6 and IL-17 expression into CCR6 
IL-17, CCR6+IL-17+, or CCR6+IL-17 subsets (as determined by secre-
tion assay labeling in L-17 secretion assay). Sorted cells (>99% pure) were 
cultured in serum-free Xvivo-15 medium (Lonza) at 37°C and 5% CO2 for 
6–7 d before restimulation with PMA and ionomycin. Culture conditions 
included: 10 U/ml recombinant human IL-2 (BD), 20 ng/ml IL-7, 20 ng/ml 
IL-15, or 20 ng/ml IL-23 (all from R&D Systems). To determine the fold 
expansion, CCR6+IL-17+ or CCR6+IL-17 subsets were labeled with CFSE 
(Invitrogen) or eFluor 670 (eBioscience), respectively, as previously described 
(Oswald-Richter et al., 2004). Alternatively, CCR6+ or CCR6 TM cells di-
rectly sorted from CD4+ T cells were either maintained in IL-7 or activated 
with aCD3/aCD28-coated beads and cultured in IL-2 containing RPMI 
1640 medium with 10% FCS (Oswald-Richter et al., 2007). In the experi-
ments  using  PI-3K  signaling  inhibitors,  cells  were  treated  with  PI-3K– 
specific inhibitor, LY294002 (EMD) or the Akt-specific inhibitor AKTi-1/2 
(EMD) for 2 d before PMA and ionomycin restimulation.
Mouse T cell isolation and culture. Wild-type C57B6/J mice were pur-
chased from The Jackson Laboratory, and all mice were used in accordance 
with a protocol approved by the animal care and use committee of Sirtris 
pharmaceuticals. Single cell suspensions were prepared from spleens and peri-
pheral lymph nodes after red blood cell lysis (Sigma-Aldrich). CD4+ T cells 
were enriched by magnetic cell sorting using the mouse CD4+ T cell isola-
tion kit II (Miltenyi Biotec) in accordance with manufacturer’s instructions, 
and these cells were stimulated for 18–24 h using plate-bound anti-CD3 
(eBioscience) and anti-CD28 (BD) antibodies as previously described (Sundrud 
et al., 2009). Activated T cells were then stained for cell surface receptors and   
subjected to mouse IL-17 capture assay for FACS sorting into CD62Llo  CCR6 
IL-17, CD62LloCCR6+IL-17, or CD62LloCCR6+IL-17+ subsets (see 
Staining and FACS analysis). Sorted mouse T cell populations were cultured   
in DME medium (Mediatech, Inc., USA) containing 10% FCS (Invitrogen). To 
expand sorted T cell populations, 10 U/ml recombinant human IL-2 (BD) 
and mouse CD3/CD28 T cell expander beads (1:2 bead/cell ratio; Invitrogen) 
were added and cells were cultured for 6 d before restimulation.
silencing of endogenous KLF2 enhanced IL-17 and IL-22 
expression by CCR6+ TM or RORC-expressing CCR6 TM 
cells. We therefore conclude that c-dependent activation of 
PI-3K and Akt drives expression of IL-17 and IL-22, prefer-
entially through a pathway that involves FOXO1 and KLF2 
down-modulation (Fig. S6; Brunet et al., 1999; Barata et al., 
2004; Fabre et al., 2005, 2008; Sinclair et al., 2008). However, 
as rapamycin treatment (Kopf et al., 2007) and mTOR defi-
ciency  (Delgoffe  et  al.,  2009,  2011)  have  been  reported   
to negatively regulate Th17 differentiation in naive mouse   
T cells, it will be of interest to determine whether mTOR 
signaling also controls Th17-signature cytokine production in 
human CCR6+ TM cells.
The mechanism by which FOXO1 and KLF2 negatively 
regulate IL-17 and IL-22 expression in human TM cells is un-
clear. The most obvious possibility is that both FOXO1 and 
KLF2 function nonredundantly as transcriptional repressors 
of IL-17 and IL-22 (Fig. S6). However, it is also plausible that 
FOXO1 regulates IL-17/IL-22 expression indirectly by in-
ducing KLF2 expression. Indeed, previous studies have shown 
that genetic ablation of Foxo1 leads to down-regulation of 
Klf2  expression  (Fabre  et  al.,  2008;  Sinclair  et  al.,  2008;   
Kerdiles et al., 2009). Consistent with these studies, we found 
that lentiviral overexpression of FOXO1 in human TM cells 
led to increased Klf2 expression (unpublished data). It will be 
important in future studies to determine the mechanism by 
which these and other transcription factors acutely regulate 
IL-17/IL-22 expression in human CCR6+ TM cells.
The negative regulation of IL-17 and IL-22 expression 
represents a novel function of KLF2. KLFs are a large family 
of zinc-finger transcription factors (Kaczynski et al., 2003; 
van  Vliet et al., 2006); they play important roles in cellular dif-
ferentiation and homeostasis (Kuo et al., 1997b; Wani et al., 
1999; Atkins and Jain, 2007; Jiang et al., 2008; Yusuf et al., 
2008; Yamada et al., 2009). KLF2 specifically has been re-
ported to maintain naive T cell quiescence and survival in 
the mouse (Anderson et al., 1995; Kuo et al., 1997a,b; Wani 
et al., 1998, 1999; Kuo and Leiden, 1999; Buckley et al., 2001;   
Di Santo, 2001; Jiang et al., 2008; Yamada et al., 2009). It also   
regulates T cell emigration from the thymus (Carlson et al., 2006; 
Sebzda et al., 2008) through regulation of S1P1 (sphingosine-1 
phosphate-1 receptor), CD62L, and the chemokine receptor 
CCR7 (Carlson et al., 2006; Sebzda et al., 2008; Weinreich   
et  al.,  2009). T  cells  from  Klf2-deficient  mice  display   
enhanced  production  of  IL-4  (Weinreich  et  al.,  2009,   
2010). In support of these findings, we observed slightly ele-
vated IL-4 production from CCR6+ TM cells after shRNA-
mediated KLF2 silencing. Moreover, statins (HMG-CoA 
reductase inhibitors), which are clinically used to treat athero-
sclerosis, have also been shown to induce KLF2 expression 
(Parmar et al., 2005). More recently, statins have been found 
to  be  broadly  antiinflammatory  and  capable  of  repressing   
IL-17 secretion (Zhang et al., 2008). In light of our findings, 
it will be important to determine whether the regulation of 
IL-17  expression  by  statins  is  achieved  through  a  KLF2- 
dependent mechanism.1884 Regulation of Th17 cytokine production by human T cells | Wan et al.
647 (Invitrogen). All data were acquired on LSRII instrument (BD) using 
FACSDiva software. Data analyses were done using FlowJo software (Tree 
Star). For phospho-Akt staining, Jurkat cells were fixed with Cytofix buffer 
(BD) prewarmed to 37°C for 10 min. After spinning down, the cells were 
permeabilized with ice-cold Phosflow Perm buffer III (BD) on ice for   
30 min and were stained with phospho-antibody.
RNA isolation and quantitative PCR. 105 purified T cells were snap fro-
zen in liquid nitrogen for total RNA isolation. Total RNA was isolated using 
RNeasy isolation kit (QIAGEN) according to the manufacturer’s protocol. 
The extracted RNA was then reverse transcribed into cDNA and quantified 
using TaqMan Cell to CT kit (Applied Biosystems). The following TaqMan 
primers and probe sets were purchased from Applied Biosystems: human 
KLF2 (Hs00360439_g1), RORC (Hs01076120_g1), Il-17a (Hs00174383_m1), 
b-Actin  (Hs03023880_g1),  and  Foxp3  (Hs00203958_m1).  Data  were   
acquired and analyzed on an ABI 7500 sequence detection system. Quantita-
tive real-time PCR data were analyzed by normalizing Ct values of genes of 
interest to the Ct values of the housekeeping gene b-actin.
Quantitative nuclease protection assay (qNPA). T cell cultures were col-
lected after PMA and ionomycin activation. Cells were resuspended at 4 × 106/
ml in sample lysis buffer (High Throughput Genomics, Inc.), heated to 95°C for 
10 min and stored at 80°C. mRNA levels were quantified in sample lysates by 
qNPA (High Throughput Genomics, Inc.) using four probes per transcript (see 
below for sequences), and samples were normalized based on abundance of a 
control (housekeeper) gene (e.g., Rpl19). Assay quality was monitored by a nega-
tive control (Arabidopsis thaliana DNA binding/transcription factor (Ant). 
Human oligonucleotide probes were generated against: the housekeeper gene 
ribosomal protein L19 (Rpl19; NM_000981), IL-17A (Il17a; NM_002190), and 
the negative control Arabidopsis thaliana DNA binding/transcription factor (Ant). 
Raw expression levels were normalized to a housekeeping gene (Rpl19). Probe 
sequences are listed below: Rpl19 (1), 5-AATGAAATCGCCAATGCCAA-
CTCCCGTCAGCAGATCCGGAAGCTCATCAA-3; Rpl19 (2), 5-TGAT-
CATCCGCAAGCCTGTGACGGTCCATTCCCGGGCTCGATGCCGG-
AAA-3;  Rpl19  (3),  5-CAGAGAAGGTCACATGGATGAGGAGAATGA-
GGATTTTGCGCCGGCTGCTC-3; Rpl19 (4), 5-CAAGCGGATTCTC-
ATGGAACACATCCACAAGCTGAAGGCAGACAAGGCCC-3;  Ant  (1), 
5-CAGTCACTGAGCTTATCCATGAGCCCTGGGTCACAATCTAGCT-
GCATCAC-3;  Ant  (2),  5-CTCCAAAGGTGGAGGATTTCTTTGG-
GACCCATCACAACAACACAAGTCAC-3; Ant (3), 5-CGAAGGAAC-
AACAACAGCATTGTCGTCAGGAATACTGAAGACCAAACCGC-3; 
Ant  (4),  5-GGGAGGTTATGATATGGAGGAGAAAGCTGCTCGAGCA-
TATGATCTTGCTG-3;  Il-17a  (1),  5-CCCTCAGGAACCCTCATCCT-
TCAAAGACAGCCTCATTTCGGACTAAACTC-3;  Il-17a  (2),  5-TAA-
CACTTGGCCAAGATATGAGATCTGAATTACCTTTCCCTCTTTC-
CAAG-3;  Il-17a  (3),  5-TGATGGTCAACCTGAACATCCATAACCG-
GAATACCAATACCAATCCCAAA-3;  Il-17a  (4),  5-CCTGGTCCTGC-
GCAGGGAGCCTCCACACTGCCCCAACTCCTTCCGGCTGG-3; 
Il-17f (1), 5-GTCATCCACCATGTGCAGTAAGAGGTGCATATCCACT-
CAGCTGAAGAAGC-3; Il-17f (2), 5-ATGACAGTGAAGACCCTGCAT-
GGCCCAGCCATGGTCAAGTACTTGCTGCT-3;  Il-17f  (3),  5-TCAA-
GGAAAGGAAGACATCTCCATGAATTCCGTTCCCATCCAGCAA-
GAGA-3; Il-17f (4), 5-GGACTCTTAATAAGACCTGCACGGATGGAA-
ACAGAAAATATTCACAATGT-3;  Il-22  (1),  5-CACTGCAGGCTTGA-
CAAGTCCAACTTCCAGCAGCCCTATATCACCAACCG-3;  Il-22  (2), 
5-GCTAAGGAGGCTAGCTTGGCTGATAACAACACAGACGTTCGT-
CTCATTGG-3;  Il-22  (3),  5-CTTCTCTTGGCCCTCTTGGTACAGG-
GAGGAGCAGCTGCGCCCATCAGCTC-3;  Il-22  (4),  5-CTCGAGTT-
AGAATTGTCTGCAATGGCCGCCCTGCAGAAATCTGTGAGCTC-3; 
Il-4 (1), 5-GGCGGGCTTGAATTCCTGTCCTGTGAAGGAAGCCAAC-
CAGAGTACGTTGG-3; Il-4 (2), 5-GCTGATAAGATTAATCTAAAGAG-
CAAATTATGGTGTAATTTCCTATGCTG-3;  Il-4  (3),  5-TTTGTCAG-
CATTGCATCGTTAGCTTCTCCTGATAAACTAATTGCCTCACA-3; 
Il-4  (1),  5-TTTCCTATTGGTCTGATTTCACAGGAACATTTTACCT-
GTTTGTGAGGCAT-3; Il-21 (1), 5-CTGAAGAGGAAACCACCTTCCA-
IL-17 secretion assay. Manufacturer’s protocols (Miltenyi Biotec) for labeling 
human and mouse IL-17–secreting cells were followed. In brief, activated   
T cells were washed in cold buffer (PBS + 0.5% BSA + 2 mM EDTA) and 
labeled with IL-17 catch reagent for 5 min on ice. Prewarmed medium was 
then added and the cells were incubated at 37°C on a shaker for 45 min. For 
human IL-17 capture experiments, cells were washed once more with cold 
buffer and PE-conjugated IL-17 detection antibodies were added and incu-
bated on ice for 10 min. For mouse IL-17 capture experiments, all steps were 
identical, except that the IL-17 detection antibody used was biotinylated, and 
a secondary staining step using APC-conjugated streptavidin was used. Cells 
were then washed and stained with additional cell surface antibodies at room 
temperature for 20 min. These cells were then washed once more with cold 
buffer, resuspended in serum-free RPMI 1640 medium, filtered, and FACS 
sorted.  Antibodies  used  for  human  IL-17  secretion  sorts  were  CCR6- 
PercpCy5.5 (cloneTG7/CCR6; BioLegend) and CD25–Alexa Fluor 700 
(clone BC96; BioLegend). Antibodies for mouse IL-17 secretion sorts were 
CD4–Pacific  orange  (Invitrogen),  CD62L–Pacific  blue  (eBioscience), 
CCR6-PE (BioLegend), IL-17A–biotin (Miltenyi Biotec), and streptavidin-
APC (eBioscience).
Plasmids and gene cloning. Full-length human KLF2 cDNA (NM_016270;   
pCMV6-XL4-KLF2; Origene) was cloned into a lentiviral vector at EcoRI   
sites. This vector consists of HIV-derived vector (HDV), an internal ribo-
some entry site (IRES), and a gene for RFP. The primers for KLF2 
amplification  were:  5  forward,  5-CCGGAATTCGCCATGGCGCT-
GAGTGAACCCATC-3; and 3 reverse, 5-CCGGAATTCCTACATGT-
GCCGTTTCATGTGCAG-3. Wild-type FOXO1 (FOXO1-GFP) was a 
gift from T.G. Unterman (University of Illinois, Chicago, IL). FOXO1-GFP 
fusion protein was engineered into HDV in frame with XbaI and XhoI sites. 
The primers for FOXO1 amplification were: 5 forward, 5-GCTCTAGAG-
CATTGCCATGGCCGAGGCGCCT-3; and 3 reverse, 5-TTCTCGAG-
GCTTACTTGTACAGCTCGTC-3. The  lentivirus-encoding  RORC 
gene, RORC-IRES-HSA, was a gift from D. Littman (Skirball Center, New 
York University School of Medicine, NY, NY). Short hairpin RNA against 
KLF2 (shKLF2; Invitrogen) was engineered into a lentiviral vector, as previ-
ously described (Antons et al., 2008), targeting position 922 in the cDNA: 
5-GGCAAGACCTACACCAAGAGT-3.
Lentiviruses production and transductions. The lentiviruses pseudo-
typed with VSV-G envelope were generated as previously described (Unutmaz   
et al., 1999). All lentiviruses expressed GFP, RFP, or heat stable antigen (HSA) 
as the marker in place of the nef gene, as previously described (Unutmaz   
et al., 1999; Oswald-Richter et al., 2004, 2007). Viral titers were measured as 
described (Unutmaz et al., 1999; Oswald-Richter et al., 2007) and ranged 
from 1–30 × 106 IFU/ml. Activated TM cells were transduced with different 
genes, such as FOXO1, KLF2, and RORC, or KLF2 shRNA and maintained 
in IL-2 containing 10% FCS RPMI 1640 medium for 14 d before reactiva-
tion with PMA and ionomycin.
Staining and FACS analysis. Cells were stained as previously described 
(Oswald-Richter et al., 2007). For intracellular staining, T cell cultures were 
stimulated for 5 h at 37°C with PMA and ionomycin and GolgiStop (BD). 
Stimulated cells were washed with PBS and stained with Fixable Viability 
Dye eFluor450 (eBioscience) to gate on live cells. Cells were then fixed and 
permeabilized  by  commercially  available  Foxp3  intracellular  staining  kit 
(eBioscience) or Cytofix/Cytoperm kit (BD) as per the manufacturer’s pro-
tocol.  Antibodies  used  for  surface  and  intracellular  staining  included: 
CD45RO-FITC; CD25-PE; IFN-–FITC (clone 4S. B3), PE Cy7, or A700; 
IL-4-APC or PE; IL-17A (IL-17)–Pacific blue (clone BL168), FITC, or   
PercpCy5.5; IL-10–APC (BioLegend); IL-22–PE (R&D Systems), or APC 
(eBioscience);  IL-21–PE  (clone  22URT1;  eBioscience);  FOXO1  rabbit 
monoclonal antibody; phospho-AKT (Ser473)–Alexa Fluor 488; Rabbit IgG 
isotype control–Alexa Fluor 488 (Cell Signaling Technology); and CCR6-
biotin (BD). Secondary antibodies used were: streptavidin-APC or Percp-
  Cy5.5 (BD); goat anti–mouse-APC (BD); and anti–rabbit–Alexa Fluor JEM Vol. 208, No. 9 
Article
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from CCR6+ TM cells. Online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20102516/DC1.
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